Founding Partner, Rustic Canyon Partners
Distinguished Professor of Law Emeritus, UCLA
Norman served as acting chancellor of UCLA in 2006-2007. He retired from the Law School faculty in 2007 with the titles of Acting Chancellor Emeritus and Distinguished Professor of Law Emeritus, but he has been recalled and continues to teach and write in the areas of anti-terrorism law, federal criminal law and evidence.
Abrams joined the UCLA Law School faculty and has been a member of the UCLA family since 1959. From 1991 to 2001 he served as UCLA's vice chancellor of academic personnel, overseeing faculty appointments and promotions on the campus. He served as interim dean of the law school from 2003 to 2004, and earlier had served as associate dean, from 1989 to 1991. In May, 2012, Abrams received the award of highest distinction conferred by the UCLA Emeriti Association, which is their Lifetime Distinguished Service Award.
The fifth edition of Abrams' groundbreaking casebook on federal criminal law, Federal Criminal Law and Its Enforcement (with Beale and Klein), was published in 2010. Another of his books, Anti-Terrorism and Criminal Enforcement, (4th edition, 2012), is the first casebook to deal comprehensively with the rapidly evolving field of anti-terrorism law and the criminal enforcement process. He is also a co-author of Evidence - Cases and Materials (with Judge Jack B. Weinstein, et al.). Over his long career, he has written on many subjects, including prosecutorial discretion, federal jurisdiction, conspiracy law, evidentiary privileges and, more recently, anti-terrorism.
Before joining UCLA, Abrams served as an associate in law at Columbia University Law School and as a research associate and director of Harvard-Brandeis Cooperative Research for Israel's Legal Development at the Harvard Law School. He has also been a consultant to various state and federal commissions and professional committees, and, while on leave from UCLA, in 1966-67, he was appointed a special assistant to the Attorney General of the United States, serving in the Criminal Division of the U.S. Department of Justice. He has taught as a visiting professor at Stanford University Law School, UC Berkeley Law School, the Hebrew University Faculty of Law, Bar-Ilan School of Law, University of Southern California Law School and Loyola University (Los Angeles) School of Law.
Executive Vice President, Amgen (Retired)
Dr. Fabrizio Bonanni retired in 2013 from his position as executive vice president at Amgen, the world’s largest independent biotechnology company. In his 14 years with Amgen, he served as senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and finally EVP Operations, overseeing the company's global production and supply chain activities as well as Quality, Process Development, Drug Delivery Devices, Engineering, and Environment, Health and Safety.
While at Amgen, Bonanni served as a Trustee of the California Science Center, of the Los Angeles Museum of Contemporary Art, of the Science Technology and Research Trust of Puerto Rico, and as a member of the Board of the California Healthcare Institute. He also served on the Executive Committee of the Board of BIO, the Biotechnology Industry Association and co-chaired its Intellectual Property Committee.
Previously, he was corporate vice president, Regulatory and Clinical Affairs and corporate vice president, Quality System for Baxter International Inc., a company he joined in 1974, in Italy. At Baxter, Bonanni spent half of his career in international operations, including more than eight years at the company's European headquarters in Brussels, Belgium.
Bonanni earned his doctorate in chemistry, summa cum laude, mention of honor, from the University of Florence and did postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management, and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration.
Currently, Dr. Bonanni is a member of the board of directors and chair of the Internal Audit Committee of the Stevanato Group, an Italian company developing and manufacturing high quality primary containers, equipment, and devices for the bio-pharma industry. He also serves on the Advisory Board of InCube Labs, a San Jose, California, based company dedicated to the discovery and development of innovative medical technologies. He is a member of the board and chair of the Audit Committee of XBiotech of Austin, Texas, an emerging biotechnology company that discovers, develops, and manufactures a novel class of therapeutic antibodies, and of Menarini Biotech, a unit of the Menarini Group, the leading Italian pharmaceutical company. In June 2016, Bonanni was appointed to the board of directors of Theranos Inc. of Palo Alto, California, where he chairs the Compliance and Quality Committee. Theranos is a health technology company dedicated to the invention, development, and commercialization of a platform of novel, miniaturized diagnostic devices
Associate Vice Provost for Research, University of Pennsylvania
Director, UCLA Jonsson Comprehensive Cancer Center
Judith C. Gasson, a professor of biological chemistry and medicine, became director of UCLA’s Jonsson Comprehensive Cancer Center in 1995. A molecular biologist, Gasson is responsible for one of only 39 institutions nationwide designated as comprehensive cancer centers by the National Cancer Institute. In addition to her administrative duties, Gasson also is a gifted scientist. She was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That substance, called GM-CSF, is used to help prevent infections in cancer patients, and to allow patients to tolerate more chemotherapy and radiation than had previously been possible. In 2005, Gasson was named a co-director of the UCLA Institute of Stem Cell Biology and Medicine and she recently testified before a key Senate subcommittee on the promise of stem cell research in cancer. Gasson also serves as a board member for the American Association for Cancer Research. She earned a bachelor’s degree in microbiology from Colorado State University and a doctorate in physiology at the University of Colorado. Gasson did post doctoral work at the Salk Institute in La Jolla. In 1983, she left the Salk Institute to join UCLA's Jonsson Cancer Center, which comprises more than 240 researchers and clinicians engaged in research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.
Division VP and Associate General Counsel at Abbott Laboratories
Founder, Paul C. Hudson Consulting
Chief Innovation Officer, Merck KGaA
Christoph Huels is responsible for the corporate innovation strategy and the technology foresight at Merck KGaA, Darmstadt, Germany. He is experienced in different businesses at Merck in Healthcare as well as Performance Materials (specialty chemicals). Including operational excellence in R&D, licensing, bio-partnering as well as the Corporate Venture Fund of Merck. Before joining Merck in 2008, he was CEO of Protagen AG, a German biotech company focussing on high value services in protein analysis especially under GMP, tool and software development for R&D in proteomics and the development of diagnostics based on a technology platform around protein biochips. He managed there several rounds of financing for the development of diagnostics as well as the build-up of a profitable service business in protein analysis. From 1999 to 2001 Christoph was responsible for project and portfolio management at Azupharma GmbH and CoKG, the German subsidiary of the Generics business of the Novartis group. He started his professional career in 1994 at Hoechst AG. After two years in the pharma division of Hoechst (today Sanofi) in Rheumatology/Immunology early phase drug development, he was working in increasing responsibility on projects in cell adhesion, protein evolution and RNA-splicing in the Central Research department. Christoph received his PhD in Biology from the Johannes-Gutenberg-University in Mainz at the Institute of Immunology.
Founder, President, CEO and Director, Adicet Bio, Inc.
Executive Chairman, AmperSand Biopharmaceuticals
Managing Partner, Aurora Capital Partners
John Mapes is the Managing Partner of Aurora Capital Partners and Chairman of the Investment Committee. He has spent his entire 23 year professional career in the financial services sector.
Aurora Capital Partners was founded in 1991. With assets under management in excess of $2.0 billion, Aurora is a private equity investment firm that invests across a number of funds in middle market companies across the country. Aurora Capital Partners is currently investing out of its sixth fund. The Firm acquires controlling interests in companies in such sectors as: specialty manufacturing, distribution and software/tech-enabled services. In addition to leading the Firm’s private equity practice, John is a member of the Firm’s Executive Committee. While he has extensive board experience with other Aurora-invested companies through the years, John currently sits on the Boards of National Technical Systems and Restaurant Technologies, Inc.
Following his graduation from UCLA with a BA degree in Economics/Business in 1990, where John played varsity tennis for the Bruins, he spent two years with Salomon Brothers, Inc. in both New York and Los Angeles, in their Corporate Finance Group. He left Salomon Brothers to join Aurora in 1992 and then rejoined the Firm after attending and graduating from Harvard Business School in 1995.
John and his wife have a son entering his sophomore year at UCLA and a daughter attending Campbell Hall High School. He has been involved in the community with the Special Olympics and the St. Matthew’s Vestry, which oversees the Church and Episcopal Day School at St. Matthew’s Church. He is also active on behalf of Harvard Business School in California.
His wife Carrie earned a BA in History in 1990 and a Master’s in Education and Multiple Subject Instruction Credential in 1991. Carrie belongs to Women & Philanthropy and is a lifetime member of the Alumni Association. The Mapes endowed five student-athlete scholarships at UCLA—two in men’s tennis, football, men’s basketball, and women’s beach volleyball. Additionally, the Mapes funded a gift to support the construction of new beach volleyball courts at UCLA which will be known on campus as Mapes Beach. John currently serves on the Athletics Centennial Campaign Committee, Chairs the UCLA Athletic Hall of Fame Committee and serves on the UCLA Technology Development Corporation Board.
Founding Partner, Sequel Venture Partners, LLC
Dean, UCLA Anderson
Chief Scientific Officer, CHDI Foundation
Robert Pacifici is the Chief Scientific Officer of CHDI Foundation, a private, not-for-profit research organization that works with an international network of scientists to accelerate therapeutics development for Huntington’s disease. Previously he was the Site Director and Chief Scientific Officer at the Research Triangle Park Laboratories of Eli Lilly and Company. There he oversaw the company's global screening and quantitative-biology efforts. Prior to joining Lilly, Pacifici was Vice President of Discovery Technologies at Xencor, a privately held biotechnology company that applied rational design principles to the development of protein therapeutics. At Amgen for nearly ten years, Pacifici held positions of increasing responsibilities including leadership for their automation, high throughput screening, and information technologies groups.
Pacifici received a BS in Biochemistry from the University of Massachusetts, Amherst, and a PhD in Biochemistry from the University of Southern California.
Outside of CHDI, Pacifici currently participates in several external boards and advisory committees including:
· USC Board of Supervisors of the International Center for Regulatory Science
· Member, Spinal Muscular Atrophy Foundation Scientific Advisory Board
· Member, Akashi Scientific Advisory Board
Pacifici has previously served on:
· Council member for National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) from 2011 till 2014
· Chair, Working Group for the NINDS Anticonvulsant Screening Program
· Chair, NIH/NINDS Spinal Muscular Atrophy Project's Scientific Steering Committee
· Advisor, Marigold Foundation for Myotonic Dystrophy
· Advisor, Cooperative International Neuromuscular Group (CINRG) the clinical research arm of the Duchenne Muscular Dystrophy Research Center (DMDRC) and the Center for Genetic Medicine Research at the Children’s National Medical Center (CNMC)
· Member, Science Advisory Board for Edison Pharmaceuticals
· Member, TREAT ALS Steering Committee
· Member, Pathogenesis of Facioscapulohumeral Muscular Dystrophy advisory board
· Panel of Experts for National Center for Advancing Translational Sciences (NCATS) at NIH, in the NIH Center for Translational Therapeutics (NCTT). This division is home to two programs that seek to advance promising therapeutic agents through late-stage preclinical development: Therapeutics for Rare and Neglected Diseases (TRND), and Bridging Interventional Development Gaps (BrIDGs)
Robert also serves in the non-scientific capacity of President with the Asia America Symphony Association. Robert, his wife Eunjoo, and his two children Sarina and Noah, live in Palos Verdes Estates California. Robert is an avid amateur road-cyclist and a classic BMW enthusiast.
Vice President and Global Head – External R&D Innovation – Pharmatherapeutics and WRD External Partnerships, Pfizer, Inc.
Barbara Sosnowski is Vice President and Global Head, External R&D Innovation Pharmatherapeutics and WRD External Partnerships. As part of the Pharmatherapeutics team, Barbara is the cluster lead for Cardiovascular Metabolic and Inflammation and Immunology Research Units for externally focused efforts. Dr. Sosnowski has more than 30 years in the health care industry. Prior to joining Pfizer 6 years ago, Barbara was Vice President, Biologics Development of Cardium Therapeutics and was appointed Chief Operating Officer of Tissue Repair Company following Cardium’s acquisition of Tissue Repair Company in August 2006. Prior to the acquisition, Dr. Sosnowski served as President and CEO of Tissue Repair Company. From June 2001 to December 2004 she served as Vice President Research and Development of Selective Genetics Inc. a tissue repair company that developed wound repair, orthopedic and cardiovascular products. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral. Prior to Selective Genetics she was employed by Prizm Pharmaceuticals from October 1992. Prior to joining Prizm, Dr. Sosnowski was at Ligand Pharmaceuticals, where her efforts were focused on identification of small molecule inhibitors of osteoporosis. Dr. Sosnowski received her BA in Biological Sciences from the University of California, Berkeley and PhD in Biological Sciences from Johns Hopkins University. She is also a registered patent agent.
Corporate VP and General Counsel, Northrop Grumman Corporation